Nasdaq

Opdivo (nivolumab) Significantly Improves Disease Free-Survival vs. Placebo as Adjuvant Therapy for Patients with High-Risk, Muscle-Invasive Urothelial Carcinoma in Phase 3 ...

Bristol Myers Squibb today announced that CheckMate -274, a pivotal Phase 3 trial evaluating Opdivo after surgery in patients with high-risk, muscle-invasive urothelial carcinoma, met its primary ...
MedPage Today

Adjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder Cancer

SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant chemotherapy, according to updated ...
Cure Today

Adjuvant Opdivo Continues to Provide Survival Benefit in Patients With High-Risk MIUC

Adjuvant nivolumab improves DFS in MIBC patients, regardless of prior neoadjuvant chemotherapy, with a median DFS of 25.6 months versus 8.5 months with placebo. Overall survival rates at 24 and 36 ...
Cure Today

An Expert Explains Updated Data For Patients With GU Cancers

Dr. Guru P Sonpavde discusses updated data from studies like EV-302 and CheckMate 274 for patients with urothelial cancer at the 2025 ASCO GU meeting. Updated data from studies like EV-302 and ...
Nasdaq

Bristol-Myers' Opdivo Meets Goals in Bladder Cancer Study

Bristol Myers Squibb BMY announced that the phase III study, CheckMate-274, on immuno-oncology drug, evaluating Opdivo, after surgery in patients with high-risk, muscle-invasive urothelial carcinoma ...